SCHEMBL13761857

SCHEMBL13761857

CCn1c2ccc(-c3ccccc3)cc2c2cc(-c3ccc(-c4ccc(-c5c6ccc(-c7ccccc7)cc6c(-c6ccc(-c7ccccc7)cc6)c6ccc(-c7ccccc7)cc56)cc4)cc3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 4/20 0.48
▸ TSPO P30536 1/20 0.48
▸ KDM4E B2RXH2 6/20 0.47
▸ RCE1 Q9Y256 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HBB P68871 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ RAC2 P15153 1/20 0.43
▸ RAC3 P60763 1/20 0.43
▸ CDC42 P60953 1/20 0.43
▸ RAC1 P63000 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ GRIK2 Q13002 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13761824 1.00 NPY5R (0.48) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761856 1.00 NPY5R (0.48) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761823 1.00 NPY5R (0.48) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761820 1.00 NPY5R (0.48) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761858 1.00 NPY5R (0.48) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761803 0.96 TSPO (0.54) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13762009 0.96 TSPO (0.54) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761843 0.96 TSPO (0.54) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761804 0.96 TSPO (0.54) NPY5RTSPOKDM4ERCE1ALDH1A1
SCHEMBL13761844 0.96 TSPO (0.54) NPY5RTSPOKDM4ERCE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9972790-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-05-15 — — US disclosed
US-9972790-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-05-15 — — US disclosed
US-20150249220-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LAB (JP) 2015-09-03 — — US disclosed
US-20150249220-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LAB (JP) 2015-09-03 — — US disclosed
US-9070883-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-30 — — US disclosed
US-9070883-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-30 — — US disclosed
US-20140212357-A1 CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-07-31 — — US disclosed
US-20130253206-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-09-26 — — US disclosed
US-20130253206-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-09-26 — — US disclosed
US-8475935-B2 — — 2013-07-02 — — US disclosed
US-8475935-B2 — — 2013-07-02 — — US disclosed
US-20090174321-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-09 — — US disclosed
US-20090174321-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-09 — — US disclosed
WO-2009081800-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140212357-A1 CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS VEGFA, MVD, FLT1 NPY5R 2161/4885TSPO 960/4885KDM4E 2300/4885
US-20150249220-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME CRY1, CYP1A1, CRY2 NPY5R 4503/4885TSPO 2908/4885KDM4E 2169/4885
US-20090174321-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME CRY1, CYP1A1, CRY2 NPY5R 4503/4885TSPO 2908/4885KDM4E 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback